Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN18SP
|
|||
| Drug Name |
MB-110
|
|||
| Synonyms |
DBPR-110; UNII-78GIB3SHQQ; 78GIB3SHQQ; 1310694-75-7; CHEMBL4468585; DBPR110; DBPR 110; SCHEMBL12547715; BDBM50522267; SB18773; Cyclopropanecarboxamide, N,N'-((1,1'-biphenyl)-4,4'-diylbis(5,2-thiazolediyl-(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))bis-; Q27266669; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenyl-acetyl]pyrrolidin-2-yl]thiazol-5-yl]phenyl]phenyl]thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenyl-ethyl]cyclopropanecarboxamide; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]phenyl]phenyl]-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Microbio
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C50H48N6O4S2
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C(C2=CC=CC=C2)NC(=O)C3CC3)C4=NC=C(S4)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CN=C(S7)C8CCCN8C(=O)C(C9=CC=CC=C9)NC(=O)C1CC1
|
|||
| InChI |
1S/C50H48N6O4S2/c57-45(37-23-24-37)53-43(35-9-3-1-4-10-35)49(59)55-27-7-13-39(55)47-51-29-41(61-47)33-19-15-31(16-20-33)32-17-21-34(22-18-32)42-30-52-48(62-42)40-14-8-28-56(40)50(60)44(36-11-5-2-6-12-36)54-46(58)38-25-26-38/h1-6,9-12,15-22,29-30,37-40,43-44H,7-8,13-14,23-28H2,(H,53,57)(H,54,58)/t39-,40-,43+,44+/m0/s1
|
|||
| InChIKey |
FZCLQOXUWMCXCV-XCIZVNRNSA-N
|
|||
| CAS Number |
CAS 1310694-75-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus Non-structural 5A (HCV NS5A) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02617615) A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Microbio. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.